Browse
Submit Data
Databases
API
Help

Dataset Information

0 Views

0 Connections

0 Citations

0 Reanalyses

0 Downloads

Omics score: 0

Proteome analysis of exosomes from WT CtBP2-HA knock-in and Mut CtBP2-HA knock-in MEF cells

ABSTRACT: We prepared two types of MEF cells: one is cells with wild-type CtBP2-HA knock-in and the other is Rossmann fold mutant CtBP2-HA knock-in. We isolated exosomes from those cells with the polymer precipitation method and subjected them to proteome analysis.

INSTRUMENT(S):

ORGANISM(S): Mus Musculus (mouse)

SUBMITTER: Motohiro Sekiya

LAB HEAD: Motohiro Sekiya

PROVIDER: PXD066696 | Pride | 2025-08-13

REPOSITORIES: Pride

ACCESS DATA

Json Xml

Dataset's files

Source:

			Action	DRS
	250605_H59376_0807A_Mut_DIA_275uL.raw	Raw
	250605_H59376_0807A_WT_DIA_275uL.raw	Raw
	H59376_807A_result.csv	Csv

Items per page:

1 - 3 of 3

Similar Datasets

Acinetobacter sp. HA strain:HA

Project description:Acinetobacter sp. HA strain:HA Genome sequencing and assembly

| PRJNA158435 | ENA

Labyrinthula sp. Ha isolate:Ha

Project description:Labyrinthula sp. Ha isolate:Ha Genome sequencing and assembly

| PRJNA607370 | ENA

The binding RNAs of Prrc2b in brain tissues of Prrc2b-HA knock-in mice [RIP-Seq]

Project description:We performed HA RIP-seq in cerebral cortexes of WT and Prrc2b-HA knockin mice at P4 to further analyze genes that Prrc2b selectively binds.

2025-09-15 | GSE243309 | GEO

miRNA array in the A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

Project description:We used miRNA microarrays to detail the miRNA content in A549 Ago2-KO/HA-Ago2Wt, Ago2-KO/HA-Ago2KA, and Ago2-KO/HA-Ago2Δ (Dm) cells

2024-04-18 | GSE255941 | GEO

HA-TFE3 bound regions in HK-2 HA-TFE3-inducible cells

Project description:TFE3 is a bHLH-ZIP transcription factor, which nuclear localization is regulated by a tumor suppressor FLCN. In order to analyze TFE3 occupancy in whole genome, we have generated and utilized a HK-2 HA-TFE3-inducible cell line which express HA-tagged TFE3 in a doxycycline-dependent manner. HA-TFE3 bound regions were determined by ChIPSeq.

2020-08-07 | GSE135490 | GEO

HA-PRCC-TFE3 bound regions in HA-PRCC-TFE3 inducible HK-2 cells

Project description:PRCC-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PRCC-TFE3-inducible HK-2 cell lines, which expresses HA-tagged TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PRCC-TFE3 by ChIPSeq.

2025-01-22 | GSE281281 | GEO

HA-PSF-TFE3 bound regions in HA-PSF-TFE3 inducible HK-2 cells

Project description:PSF-TFE3 is an oncogenic chimeric transcription factor derived from human TFE3-rearranged renal cell carcinoma. To analyze its genome-wide occupancy, we developed HA-tagged PSF-TFE3-inducible HK-2 cell lines, which expresses HA-tagged PSF-TFE3 in a doxycycline-dependent manner. We determined the binding regions of HA-PSF-TFE3 by ChIPSeq.

2025-08-18 | GSE297289 | GEO

Trial of FOLF(HA)Iri With Cetuximab in mCRC

Project description:As an approach to improve efficacy and provide clinical benefit to cancer patients undergoing chemotherapeutic treatment regimens, Alchemia Oncology has developed a novel means for delivering anti-cancer agents to tumours. The drug delivery platform is based on the use of hyaluronic acid (HA), a novel excipient, in which, formulation with HA results in optimisation of cytotoxic drug uptake and retention within solid tumours. In the specific example of HA-Irinotecan, this new formulation of irinotecan has demonstrated enhanced efficacy in both nonclinical and early clinical studies. The current study is an investigation into the use of HA-Irinotecan in a Phase II single arm trial of FOLF(HA)iri plus cetuximab in irinotecan-naïve second line patients with KRAS wild type metastatic colorectal cancer. The study objectives are to confirm the safety and efficacy of FOLF(HA)iri plus cetuximab as second-line therapy in irinotecan-naïve metastatic colorectal cancer patients. It is expected that the study recruit approximately 40-50 patients in 1 year with subsequent treatment and follow up; thus the trial will run for approximately 2-3 years.

| 2172573 | ecrin-mdr-crc

Aeromicrobium sp. HA

Project description:Aeromicrobium sp. HA Assembly

| PRJNA911185 | ENA

Transcriptome of MEF cells with or without Fbxw7 knock out

Project description:This study describes the transcriptome profiling of MEF cells with or without Fbxw7 knock out

2023-12-30 | GSE164135 | GEO